{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:27:35Z","timestamp":1793654855265,"version":"4.5.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370196"],"award-info":[{"award-number":["82370196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070213"],"award-info":[{"award-number":["82070213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.10.001","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:13:33Z","timestamp":1791756813000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in CAR-T and CAR-NK Cell Therapy in Follicular Lymphoma: A Review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6634-3265","authenticated-orcid":false,"given":"Sijia","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jtct.2026.10.001_bib0001","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.jtct.2026.10.001_bib0002","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/blood.2024026016","article-title":"An updated understanding of follicular lymphoma transformation","volume":"146","author":"Parry","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.001_bib0003","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/S2352-3026(25)00034-1","article-title":"Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial","volume":"12","author":"Northend","year":"2025","journal-title":"Lancet Haematol"},{"issue":"15","key":"10.1016\/j.jtct.2026.10.001_bib0004","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood.2024026019","article-title":"Frontline treatment of follicular lymphoma: what will it take to change current practice?","volume":"146","author":"Bachy","year":"2025","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.jtct.2026.10.001_bib0005","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.001_bib0006","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.10.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.06.013","article-title":"Evaluating the role of CAR-T cell therapy in the context of current therapy options for patients with relapsed or refractory follicular Y lymphoma","author":"Chavez","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"10.1016\/j.jtct.2026.10.001_bib0008","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jtct.2026.10.001_bib0009","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic specialized program of research excellence molecular epidemiology resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol"},{"issue":"S2","key":"10.1016\/j.jtct.2026.10.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70070","article-title":"Follicular lymphoma: current therapeutic landscape and future prospects","volume":"43","author":"Kumar","year":"2025","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.001_bib0012","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.001_bib0013","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0014","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in Relapsed or Refractory Indolent Non-hodgkin Lymphoma (ZUMA-5): a Single-arm, multicentre, Phase 2 Trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.10.001_bib0015","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.001_bib0016","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharm Med"},{"key":"10.1016\/j.jtct.2026.10.001_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1615212","article-title":"Tracing the development of CAR-T cell design: from concept to next-generation platforms","volume":"16","author":"Alsaieedi","year":"2025","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jtct.2026.10.001_bib0018","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.17305\/bb.2026.14266","article-title":"CAR-T cell therapy in cancer immunotherapy \u2013 biology, clinical successes, and emerging challenges: a review","volume":"26","author":"Bedada","year":"2026","journal-title":"Biomol Biomed"},{"key":"10.1016\/j.jtct.2026.10.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-026-03081-3","article-title":"Tisa-cel and Axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy","author":"Krawczyk","year":"2026","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.001_bib0020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0021","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12967-023-04372-4","article-title":"Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality","volume":"21","author":"Smith","year":"2023","journal-title":"J Transl Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.001_bib0022","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.001_bib0023","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00668","article-title":"Five-year follow-up analysis of ZUMA-5: axicabtagene ciloleucel in relapsed\/refractory indolent non-hodgkin lymphoma","author":"Neelapu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jtct.2026.10.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181893","article-title":"Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma","volume":"135","author":"Poddar","year":"2025","journal-title":"J Clin Invest"},{"issue":"17","key":"10.1016\/j.jtct.2026.10.001_bib0026","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2026.10.001_bib0027","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2022008150","article-title":"Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma","volume":"6","author":"Salles","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.001_bib0028","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0173","article-title":"Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed\/refractory follicular lymphoma","volume":"12","author":"Hao","year":"2023","journal-title":"J Comp Eff Res"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.10.001_bib0029","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2023-184653","article-title":"Real-word experience of CAR T-cells in patients with relapsed\/refractory follicular lymphoma\u202f: a descart registry analysis from the lysa","volume":"142","author":"Ysebaert","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.001_bib0030","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/bjh.70025","article-title":"Real-world experience with CAR -T therapy in relapsed and refractory follicular lymphoma","volume":"207","author":"Triantafilo","year":"2025","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.10.001_bib0031","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2023-178629","article-title":"Comparative effectiveness of axicabtagene ciloleucel vs historical standard-of-care in patients with relapsed or refractory follicular lymphoma: an analysis of CIBMTR and SCHOLAR-5 data","volume":"142","author":"Kambhampati","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.001_bib0032","doi-asserted-by":"crossref","first-page":"885.e1","DOI":"10.1016\/j.jtct.2024.06.016","article-title":"Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed\/refractory follicular lymphoma","volume":"30","author":"Ray","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0033","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40164-025-00610-1","article-title":"Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma","volume":"14","author":"Nastoupil","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.001_bib0034","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26711","article-title":"Preliminary efficacy and safety of relmacabtagene Autoleucel (carteyva) in adults with relapsed\/refractory follicular lymphoma in China: a phase I\/II clinical trial","volume":"97","author":"Ying","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.001_bib0035","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/bjh.20122","article-title":"Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study","volume":"207","author":"Song","year":"2025","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.001_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70051","article-title":"Survival benefit of relmacabtagene autoleucel versus usual care in relapsed\/refractory follicular lymphoma: a matching-adjusted indirect analysis","volume":"43","author":"Gao","year":"2025","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.001_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70166","article-title":"Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed\/refractory follicular lymphoma","volume":"9","author":"Mart\u00ednez-Cibri\u00e1n","year":"2025","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010792","article-title":"T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes","volume":"13","author":"Bartol\u00f3-Ibars","year":"2025","journal-title":"J ImmunoTher Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.10.001_bib0039","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2023-175007","article-title":"Efficacy and safety of a third generation CD20 CAR-T (MB-106) for treatment of relapsed\/refractory indolent B-cell non-Hodgkin lymphoma: phase-1 results from a multicenter trial","volume":"142","author":"Shadman","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.10.001_bib0040","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2021-149181","article-title":"Safety and efficacy of third generation CD20 targeted CAR-T (MB-106) for treatment of relapsed\/refractory B-NHL and CLL","volume":"138","author":"Shadman","year":"2021","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.jtct.2026.10.001_bib0041","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hon.3163_49","article-title":"High efficacy and favorable safety of 3rd generation cd20 Car-t (mb-106) for outpatient treatment of follicular lymphoma (fl)\u2014results of a single-institution trial","volume":"41","author":"Shadman","year":"2023","journal-title":"Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.10.001_bib0042","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2024-198489","article-title":"CD22-directed CAR T-cell therapy achieves complete remission in CD19-directed CAR T-cell refractory follicular and mantle cell lymphoma","volume":"144","author":"Kramer","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.001_bib0043","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1016\/j.jtct.2025.01.599","article-title":"CD22-directed CAR T-cell therapy achieves complete remission in CD19-directed CAR T-cell refractory follicular and mantle cell lymphoma with superior safety and absence of neurotoxicity","volume":"31","author":"Srinagesh","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.001_bib0044","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007515","article-title":"Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas","volume":"11","author":"Chu","year":"2023","journal-title":"J ImmunoTher Cancer"},{"issue":"23","key":"10.1016\/j.jtct.2026.10.001_bib0045","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-19-1337","article-title":"Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19","volume":"25","author":"Ormh\u00f8j","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2026.10.001_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.10.001_bib0047","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2024-198416","article-title":"Favorable safety profile and durable responses to pmb-CT01 (BAFFR-CAR T cell) therapy in patients with B-cell lymphomas ineligible for or who failed CD19-targeted therapy, including CD19-negative disease","volume":"144","author":"Del Real","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.001_bib0048","article-title":"CXCL13-CXCR5 axis: regulation in inflammatory diseases and cancer","volume":"1877","author":"Wang","year":"2022","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0049","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-020-20488-3","article-title":"CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin\u2019s lymphoma and tumor-supportive follicular T helper cells","volume":"12","author":"Bunse","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2026.10.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102555","article-title":"CD70-targeted CAR-T\/NK therapy: rationale, advances, and future directions","volume":"62","author":"Yan","year":"2025","journal-title":"Transl Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.001_bib0051","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cac2.12201","article-title":"CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell lymphoma","volume":"41","author":"Deng","year":"2021","journal-title":"Cancer Commun"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.001_bib0052","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0053","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/s12967-025-06567-3","article-title":"Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed\/refractory B cell non-Hodgkin lymphoma","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"issue":"14","key":"10.1016\/j.jtct.2026.10.001_bib0054","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood.2024026401","article-title":"A phase 1 trial of prizloncabtagene autoleucel, a CD19\/CD20 CAR T-cell therapy for relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"145","author":"Yu","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0056","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","article-title":"ARI0003: co-transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of non-hodgkin lymphoma","volume":"33","author":"Bachiller","year":"2025","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0057","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","article-title":"CAR-T cell combination therapies in hematologic malignancies","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0058","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40164-024-00551-1","article-title":"Current and future therapies for follicular lymphoma","volume":"13","author":"Zinzani","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.001_bib0059","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/cas.14915","article-title":"Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-hodgkin lymphoma","volume":"112","author":"Liu","year":"2021","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.001_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.049","article-title":"Acalabrutinib in combination with Anti-CD19 chimeric antigen receptor T-cell therapy in relapsed\/refractory B-cell lymphoma: a phase I\/II study of safety, efficacy and immune correlative analysis","volume":"30","author":"Poh","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.001_bib0061","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00277-023-05255-w","article-title":"Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R\/R FL","volume":"102","author":"Ye","year":"2023","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.10.001_bib0062","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1182\/blood-2024-205304","article-title":"BTK inhibitor synergizes with CD19-targeted chimeric antigen receptor-T cells in patients with relapsed or refractory B-cell lymphoma: an open-label pragmatic clinical trial","volume":"144","author":"Luo","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.001_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116532","article-title":"Efficient combination of radiotherapy and CAR-T \u2013 a systematic review","volume":"174","author":"Szlasa","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.001_bib0064","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","article-title":"Don\u2019t put the CART before the horse: the role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-hodgkin lymphoma","volume":"116","author":"Saifi","year":"2023","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"13","key":"10.1016\/j.jtct.2026.10.001_bib0065","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/bloodadvances.2025015855","article-title":"Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study","volume":"9","author":"Yegya-Raman","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.001_bib0066","doi-asserted-by":"crossref","first-page":"505","DOI":"10.21147\/j.issn.1000-9604.2025.04.03","article-title":"Bridging transplantation and immunotherapy: clinical promise of autologous stem cell transplantation with chimeric antigen receptor T-cell therapy","volume":"37","author":"Yan","year":"2025","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.jtct.2026.10.001_bib0067","article-title":"Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory\/relapsed B-cell lymphoma: a single-arm clinical study","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.001_bib0068","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.2023022682","article-title":"CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models","volume":"144","author":"Brinkmann","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.001_bib0069","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.001_bib0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009048","article-title":"CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression","volume":"13","author":"Arroyo-R\u00f3denas","year":"2025","journal-title":"J ImmunoTher Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0071","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.jtct.2026.10.001_bib0072","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase I experience from the ALPHA2\/ALPHA clinical studies","volume":"43","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.001_bib0073","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat Immunol"},{"issue":"30","key":"10.1016\/j.jtct.2026.10.001_bib0074","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add6997","article-title":"Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40164-024-00522-6","article-title":"CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison","volume":"13","author":"Egli","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.10.001_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112156","article-title":"IL-15 as a key regulator in NK Cell-mediated immunotherapy for cancer: from bench to bedside","volume":"133","author":"Vahidi","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.001_bib0077","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00262-025-04191-0","article-title":"CAR NK cell production from human cord blood NK progenitor cells is enhanced by stimulation of the IL-15 receptor","volume":"74","author":"Kogue","year":"2025","journal-title":"Cancer Immunol, Immunother"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.001_bib0078","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.001_bib0079","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"issue":"10473","key":"10.1016\/j.jtct.2026.10.001_bib0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jtct.2026.10.001_bib0081","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.2021015184","article-title":"Dual antigen\u2013targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.001_bib0082","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010822","article-title":"Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K\/AKT\/mTOR signal signature","volume":"13","author":"Wang","year":"2025","journal-title":"J ImmunoTher Cancer"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.001_bib0083","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41375-019-0663-x","article-title":"Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma","volume":"34","author":"Ravi","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.001_bib0084","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jcyt.2024.06.001","article-title":"IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy","volume":"26","author":"Biggi","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.10.001_bib0085","article-title":"Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing","author":"Wang","year":"2024","journal-title":"Bioengineering"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0086","article-title":"CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.001_bib0087","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the Treatment of CD19-negative B-cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.10.001_bib0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5562630","article-title":"Selective cytotoxicity of single and dual anti-CD19 and anti-CD138 chimeric antigen receptor-natural killer cells against hematologic malignancies. Xu B, Ed","volume":"2021","author":"Luanpitpong","year":"2021","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.001_bib0089","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","article-title":"Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells","volume":"20","author":"Roex","year":"2022","journal-title":"J Transl Med"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:31:50Z","timestamp":1793651510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726007839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":89,"alternative-id":["S2666636726007839"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in CAR-T and CAR-NK Cell Therapy in Follicular Lymphoma: A Review","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}